Sylvie Grégoire

Member of the Board, member of the Audit Committee, member of the Nomination Committee and member of the Research & Development Committee
Sylvie Grégoire, Member of the Board, member of the Audit Committee, member of the Nomination Committee and member of the Research & Development Committee


Sylvie Grégoire is former president of Human Genetic Therapies Shire PLC, US and Switzerland from 2007 to 2013. Prior to that, she was executive chairman of IDM Pharma Inc., US, from 2006 to 2007, and president and chief executive officer in GlycoFi Inc., US from 2003 to 2004. From 1995 until 2003 Ms Grégoire held various leadership positions in Biogen, Inc., in France and the US, recently as executive vice president of Technical Operations. Prior to this, Ms Grégoire was at Merck and Co, in clinical research and regulatory affairs in Canada, US and Belgium for a period of 8 year prior.

Ms Grégoire serves as chairman of the board of Corvidia Therapeutics Inc., US. Further, Ms Grégoire serves as a member of the board of Vifor Pharma Ltd., Switzerland and of the board of Perkin Elmer Inc., US.

Ms Grégoire has a Pharmacy Doctorate degree from the State University of NY at Buffalo, US, from 1986, a B.A. in Pharmacy from Laval University, Canada, from 1984 and a Science College degree from Seminaire de Sherbrooke, Canada, from 1980.

Ms Grégoire was first elected to the Board of Novo Nordisk A/S in March 2015 and has most recently been re-elected in 2018. Her term as a board member expires in March 2019.

In March 2018, the Board of Directors of Novo Nordisk A/S assessed that Ms Grégoire is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen.

Ms Grégoire became member of the Audit Committee at Novo Nordisk A/S in March 2015. In March 2018, the Board of Directors of Novo Nordisk A/S assessed that Ms Grégoire qualifies as independent pursuant to the US Securities Exchange Act.

Ms Grégoire became member of the Research & Development Committee at Novo Nordisk A/S at the establishment in March 2017 and Ms Grégoire became member of the Nomination Committee at Novo Nordisk A/S in March 2018.

In January 2018, the Board of Directors assessed that the special competences possessed by Ms Grégoire that are important for the performance of her duties are her deep knowledge of the regulatory environment in both the US and the EU, having experience with all phases of the product life cycle, including discovery, registration, pre-launch and managing the life cycle while on the market. In addition, Ms Grégoire has financial insight including into P&L responsibility.

Ms Grégoire is a female Canadian and US national, born November 1961.